Tyson Foods Inc. (TSN) Falls 3.4% for January 19

Equities Staff |

One of the S&P 500’s big losers for Tuesday January 19 was Tyson Foods Inc. (TSN). The company’s stock fell 3.4% to $49.74 on volume of 4.49 million shares.

The stock opened the day at 51.52 and traded between a low of $49.32 and a high of $52.09. The stock finished the day down $1.75 per share. Tyson Foods Inc. has an average daily volume of 4.65 million and a total float of 365.66 million shares. The 50-day SMA for Tyson Foods Inc. is $50.27 and its 200-day SMA is $44.22. The high for the stock over the last 52 weeks is $54.42 and the low is $37.10.

Tyson Foods Inc and its subsidiaries produce, distributes and markets chicken, beef, pork, prepared foods and related allied products, including animal and pet food ingredients.

Tyson Foods Inc. is centered in Springdale, AR, and has 113,000 employees. Today’s trading day leaves the company with a market cap of $18.19 billionwith a P/E Ratio of 17.5. The company has a P/S ratio of 0.62, P/B ratio of 1.88, and a 13.2.

For a complete fundamental analysis analysis of Tyson Foods Inc., check out Equities.com’s Stock Valuation Analysis report for TSN. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


Uber connects riders with safe, reliable, convenient transportation providers at a variety of price-points in cities around the world. Uber makes money from charging their drivers 20% of the fare…

Almond Smart Home Router by Securifi

Securifi sells user friendly touch screen routers that also have support for IoT/home automation.Securifi’s Almond revolutionized wireless router setup with its easy to use Touchscreen Interface in 2012. Now our…